Compare Recursion Pharmaceuticals Inc (RXRX) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vale SA — how do they compare? Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B), while Vale SA trades at $13.5 (market cap $58.70B). The key difference: Vale SA is far larger — about 25.4× Recursion Pharmaceuticals Inc's market cap, and Vale SA pays a 8.75% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Vale SA for 109 Days on average.
| RXRX | VALE | |
|---|---|---|
Market Cap | $2.31B | $58.70B |
Volume | 40,478,768 | 45,073,516 |
Sector | Health | Basic Materials |
52-Week High | $6.79 | $17.82 |
52-Week Low | $2.84 | $10.75 |
Typical Hold Time | 22 Days | 109 Days |
Enterprise Value | $1.83B | $74.94B |
Dividend Yield | — | 8.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
VALE trades at $13.42, down 4.69% today amid broader sector weakness. The stock shows bearish technical signals with recent earnings misses and declining profit margins (5.11% net margin in 2025). Revenue has stabilized around $38-41B, but net income fell to $2.35B in 2025 from $18.8B in 2022. The company maintains strong cash flow generation ($8.8B operating cash flow) and recently declared a $0.40 dividend payable September 2026.
VALE faces headwinds from iron ore price volatility and rising costs, but base metals growth provides diversification. Analyst consensus is mixed with 32% buy ratings and a $16.21 price target suggesting 21% upside. Key risks include Brazilian regulatory exposure and cyclical commodity dependence. The current valuation (P/E 27.22) appears stretched given earnings compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
